First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
March 22, 2024 04:00 ET
|
Molecure
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the...
Alvotech heldur uppgjörsfund fyrir árið 2023 í beinu streymi þann 21. mars nk. kl. 12:00 að íslenskum tíma
March 05, 2024 16:01 ET
|
Alvotech
Fjárfestadagur, sem einnig verður sendur út á vefnum, verður haldinn föstudaginn 22. mars nk. Alvotech (NASDAQ: ALVO) birtir ársuppgjör fyrir 2023 að kvöldi miðvikudagsins 20. mars nk., eftir lokun...
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
March 05, 2024 16:01 ET
|
Alvotech
Alvotech to host Capital Markets Day in Reykjavik and on-line on March 22, 2024 Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar...
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
March 04, 2024 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alvotech Appoints Interim Chief Quality Officer
February 29, 2024 16:05 ET
|
Alvotech
REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Cybrexa Regains Rights to CBX-12
February 06, 2024 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
January 29, 2024 04:00 ET
|
Alvotech
The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpoints Prolia® and Xgeva® (denosumab) are indicated...
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
January 19, 2024 11:30 ET
|
Alvotech
REYKJAVIK, Iceland, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
January 03, 2024 03:30 ET
|
Alvotech
The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients with neovascular (wet) Age-related Macular...
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
January 02, 2024 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Jan. 02, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...